Abstract
The adenosine A2A receptor (A2AR) is highly concentrated in the striatum, and a therapeutic target for Parkinson’s disorder (PD) and Huntington’s disease. High affinity and selective radiolabeled A2AR antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A2A antagonists non-invasively in the brain. However, till date no complete review on A2AR PET ligands is available. The present article has been therefore focused on available PET tracers for A2AR and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A2ARs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A2AR for PD has also been presented.
Keywords: Adenosine A2A receptor, Parkinson’s disorder, positron emission tomography (PET), xanthine ligands, nonxanthine ligands, SCH442416, TMSX, 6-OHDA PD model.
Current Medicinal Chemistry
Title:Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Volume: 21 Issue: 3
Author(s): S. Khanapur, A. van Waarde, K. Ishiwata, K. L. Leenders, R. A.J.O. Dierckx and P. H. Elsinga
Affiliation:
Keywords: Adenosine A2A receptor, Parkinson’s disorder, positron emission tomography (PET), xanthine ligands, nonxanthine ligands, SCH442416, TMSX, 6-OHDA PD model.
Abstract: The adenosine A2A receptor (A2AR) is highly concentrated in the striatum, and a therapeutic target for Parkinson’s disorder (PD) and Huntington’s disease. High affinity and selective radiolabeled A2AR antagonists can be important research and diagnostic tools for PD. Positron Emission Tomography (PET) can play an important role by measuring radiolabeled A2A antagonists non-invasively in the brain. However, till date no complete review on A2AR PET ligands is available. The present article has been therefore focused on available PET tracers for A2AR and their detailed biological evaluation in rodents, nonhuman primates and humans. Drug design and development by molecular modeling including new lead structures that are potential candidates for radiolabeling and mapping of cerebral A2ARs is discussed in the present article. A brief overview of functions of adenosine in health and disease, including the relevance of A2AR for PD has also been presented.
Export Options
About this article
Cite this article as:
Khanapur S., Waarde van A., Ishiwata K., Leenders L. K., Dierckx A.J.O. R. and Elsinga H. P., Adenosine A2A Receptor Antagonists as Positron Emission Tomography (PET) Tracers, Current Medicinal Chemistry 2014; 21 (3) . https://dx.doi.org/10.2174/09298673113206660265
DOI https://dx.doi.org/10.2174/09298673113206660265 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Effect of Serotonin 5-HT2 Receptor Inhibitor on Vasomotor Responses
Vascular Disease Prevention (Discontinued) PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives
Anti-Infective Agents L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Vascular Disease Prevention (Discontinued) Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Current Pharmaceutical Design Development and Optimization of Controlled Release Bioerodable Anti Infective Ophthalmic Insert
Current Drug Delivery Optimization and Validation of Polyherbal Formulation by Applying Boxbehnken Design for the Treatment of Inflammatory Bowel Disease in Experimental Animals
Current Drug Therapy Vasomotor Effects of Iodinated Contrast Media: Just Side Effects?
Current Vascular Pharmacology Conductance and Resistance Vessels in Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Air Pollution Exposure and Blood Pressure: An Updated Review of the Literature
Current Pharmaceutical Design Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration
Current Neuropharmacology Anti-VEGF Treatment in Corneal Diseases
Current Drug Targets Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Current Medicinal Chemistry Therapeutic Effects and Mechanisms of Action of Cyclosporine A Ophthalmic Solution in the Treatment of Vernal Keratoconjunctivitis
Current Pharmaceutical Analysis Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Anti-Inflammatory Drugs and Statins for Arterial Stiffness Reduction
Current Pharmaceutical Design Recent Advances in Developing Ophthalmic Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation